Navigation Links
MicroRNA regulation of tumor-killing viruses avoids unwanted viral pathology
Date:5/21/2009

Scientists have determined how to produce replication-competent viruses with key toxicities removed, providing a new platform for development of improved cancer treatments and better vaccines for a broad range of viral diseases.

Cellular microRNA molecules regulate the stability of mRNA in different cell types, and this newly-understood mechanism provides the possibility to engineer viruses for cell-specific inactivation. Cancer Research UK scientists at the University of Oxford, United Kingdom, with support from colleagues at Vrije Universiteit, Amsterdam, report that this approach can be used to regulate proliferation of adenovirus in a study published May 22 in the open-access journal PLoS Pathogens.

Adenovirus is a DNA virus widely used in cancer therapy but which causes hepatic disease in mice. Professor Len Seymour and colleagues found that introducing sites into the virus genome that are recognized by microRNA 122 leads to hepatic degradation of important viral mRNA, thereby diminishing the virus' ability to adversely affect the liver, while maintaining its ability to replicate in and kill tumor cells.

Tumor-killing replicating viruses are a hot topic in the biotherapeutics arena, with many clinical trials ongoing worldwide. That Professor Seymour's group set out to and has now defined a mechanism whereby wild type virus potency could be maintained in tumor cells but the virus could be 'turned off' in tissues vulnerable to pathology adds important information to the current base of knowledge.

"This approach is surprisingly effective and quite versatile. It could find a range of applications in controlling the activity of therapeutic viruses, both for cancer research and also to engineer a new generation of conditionally-replicating vaccines, where the vaccine pathogen is disabled in its primary sites of toxicity," Professor Seymour says.

The present study was intended mainly to explore and demonst
'/>"/>

Contact: Emma Gilgunn-Jones
emma.gilgunn-jones@cancer.org.uk
44-207-061-8311
Public Library of Science
Source:Eurekalert

4

GOOD

Page: 1 2

Related medicine news :

1. Exiqon Announces New Grant Program for MicroRNA Research
2. Throwing the micro switch: MicroRNA may link smoking risk gene to neurobiology of addiction
3. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer
4. MicroRNA undermines tumor suppression
5. MicroRNAs make for safer cancer treatments
6. Gladstone scientists identify single microRNA that controls blood vessel development
7. Putting microRNAs on the stem cell map
8. Need microRNA processing? Get Smad
9. MicroRNA controls expression of oncogenes
10. MicroRNAs appear essential for retinal health
11. MicroRNAs, EMT and cancer progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Haemonetics Corporation (NYSE: HAE ) announced ... action to stop Fenwal Inc.,s continued patent infringement ... kits, using a modified separation chamber. Fenwal ... patent and the injunction entered by the Court ... December 1, 2010. According to statements made ...
(Date:12/14/2009)... Calif., Dec. 14 Tough Enough To Wear ... breast cancer, celebrated its fifth anniversary at the ... the Wrangler National Finals Rodeo (Wrangler NFR) in ... with rough-and-tumble rodeo cowboys, the support of the ... the sold-out crowd sported pink shirts, hats, bracelets ...
(Date:12/14/2009)... Staff , ... La Jolla, Calif. (Vocus) -- The ... MD, as the new chief of staff of the 372-bed facility. ... team on Jan. 1, 2010. , , , , ,During his ... Scripps La Jolla’s administrative staff and its board of directors. Dr. ...
(Date:12/14/2009)... Critical to Stemming Tide of Tens of Thousands ... WASHINGTON, Dec. 14 Legislation approved by ... will be crucial in helping to reduce tens ... each year in the United States, the ... The provision was included in the FY ...
(Date:12/14/2009)... Dec. 14 When Kurth Krause, an ... instructions for landing on the moon, he,was confident ... anything.,Years later, Kurth realized there was one thing ... kidney transplant and even though dialysis machines,would keep ... a transplant. Kurth,wrote: "My wife is 69 and ...
Breaking Medicine News(10 mins):Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3
... and post-stem cell transplantation results compared to thalidomide and ... ... Pharmaceuticals,Inc. (Nasdaq: MLNM ) reported the presentation of results from ... randomized,Phase III clinical trial. This study compared VELCADE, thalidomide and,dexamethasone (VcTD) ...
... approved for use as second line therapy for chronic myelogenous ... diagnosed patients in two clinical trials, research teams led by ... Center report at the 49th annual meeting of the American ... trials have a complete cytogenetic response - absence of the ...
... LOS ANGELES, Dec. 9 A federal court ... a harsh spotlight on the pharmaceutical firm,Johnson & ... of,false advertising the controversial chemical sweetener Splenda. United,States ... request for,summary judgment based on that charge that ...
... with high levels of D-dimer face greatest chance of ... Levels of certain blood markers may increase the risk ... relieve symptoms of menopause, new research shows. , ... whether to take the hormone therapy, said the authors ...
... FL, December 8, 2007 A series of studies ... annual meeting elucidates evidence that there is a genetic ... scientific explanation for lower rates of cancer among patients ... rates of smoking and their parents. ...
... arson is a reminder that we must remain vigilant,in ... safety of,the dedicated health care professionals who provide that ... a,statement of Vicki Saporta, President and CEO of the ... Curtis Boyd, MD, in Albuquerque,NM:, As the professional ...
Other Medicine News:Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:Federal Judge Says Sugar Association Suit Accusing Johnson & Johnson of False Advertising to Go Forward 2Health News:Blood Markers Might Predict Clotting Risk With HRT 2Health News:Blood Markers Might Predict Clotting Risk With HRT 3Health News:Studies elucidate genetic links between cancer and schizophrenia 2
(Date:12/14/2009)... 14 In response to an ... in which the Agency recommended that healthcare facilities ... sterile processing system, hospitals throughout the U.S. are ... to that product. According to the FDA, STERIS ... that may affect the safety or the effectiveness ...
(Date:12/14/2009)... -- Following is a statement by Linda A. ... Association (CHPA), regarding today,s release of the National ... survey: ,, "Findings released today on this year,s ... for continued efforts to educate and empower parents ... their teens about medicine abuse. The Consumer Healthcare ...
(Date:12/14/2009)... The board of directors of Eli Lilly ... a dividend for the first quarter of 2010 of ... ,, The dividend is payable March 10, 2010 to ... ,, February 12, 2010. ,, Lilly, a leading ... products by applying the latest research from its own ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 1Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 1Protein handlers should be effective treatment target for cancer and Alzheimers 9501 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 3America Takes on the Challenge to Fight Obesity 53865 1America Takes on the Challenge to Fight Obesity 53865 2America Takes on the Challenge to Fight Obesity 53865 3America Takes on the Challenge to Fight Obesity 53865 4
... lowest dose groups show dose-dependent PSA ... declines to date in all patients - - ... SAN FRANCISCO, Nov. 5 Medivation, Inc.,(Nasdaq: MDVN ) today ... levels of prostate specific,antigen (PSA), a marker of tumor growth, in the ...
... non-responders to previous interferon-based therapy -, - SVR results in ... non- responders, with less frequent dosing -, - ... American Association for the Study of Liver Diseases ... (AASLD) -, ROCKVILLE, Ma., Nov. 5 ...
Other Medicine Technology:Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 2Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 3Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... This latest sensor array with ... inter-channel spacing of just 2.2 ... is particularly useful when using ... Synthetic Aperture Magnetometry (SAM) or ...
... supine measurement position is achieved using an ... a non-magnetic, mobile patient bed. The patient ... shielded room. In case of an emergency ... the shielded room for e.g. resuscitation purposes. ...
... The Magnes 1300 C is ideal for ... brain and other parts of the body. Often ... its possibilites, including magnetocardiography, gastrointestinal tract, fetal, spinal ... ,The 1300 C, with its 67 detector ...
... one-of-kind portable Digital Radiography system designed for diverse ... a 14 x 17- inch imaging area and ... large imaging area and lightweight design, the CXDI-50G ... Radiography. It is large enough for chest and ...
Medicine Products: